Pharmacology for Nurses

Course Overview

Pharmacology for Nurses is an intermediate-level course designed to develop the pharmacological knowledge, clinical reasoning, and safe practice habits expected of the BSN-prepared nurse. Medication management is one of the most complex and highest-risk activities in clinical nursing: it requires mathematical accuracy, mechanistic understanding of how drugs work, pattern recognition for adverse effects, and the judgment to withhold, administer, question, and educate — often simultaneously and under time pressure.

This course is organized around eight modules that move from foundational science through drug calculation proficiency, major drug class mastery, and safe administration guidelines, culminating in case-based clinical application. Throughout, content references the Pharmacology Fundamentals encyclopedia entry for deeper scientific detail and the pharmacology drug reference collection for individual agent monographs.

Alignment with national standards is explicit throughout: course objectives, assessments, and clinical cases are mapped to the AACN Essentials (2021), the NCLEX-NG Clinical Judgment Measurement Model (CJMM), and QSEN competencies — in particular Patient-Centered Care, Safety, and Evidence-Based Practice.

---

Learning Objectives

By the end of this course, students will be able to:

1. Recall the four pharmacokinetic processes (ADME) and explain how each affects drug selection, dosing, and monitoring in diverse patient populations. (Bloom’s: Remember/Understand — AACN D1, D6)
2. Apply dimensional analysis to accurately calculate drug doses, IV infusion rates, and weight-based doses for adult and pediatric patients. (Bloom’s: Apply — AACN D3, D6)
3. Identify the major drug classes, their primary mechanisms of action, therapeutic uses, and clinically significant adverse effects. (Bloom’s: Understand — AACN D1, D9)
4. Apply the six rights of medication administration and the pre-administration safety checklist to every clinical medication encounter. (Bloom’s: Apply — AACN D2, D6; QSEN S)
5. Analyze clinical scenarios to recognize drug interactions, adverse drug reactions, and signs of toxicity, and select appropriate nursing interventions. (Bloom’s: Analyze — NCLEX-NG CJMM: Prioritize Hypotheses, Take Action)
6. Evaluate patient-specific factors — including age, organ function, genetics, and polypharmacy — that require individualized pharmacological management. (Bloom’s: Evaluate — AACN D1, D4; QSEN EBP)
7. Demonstrate safe medication administration practices for high-alert medications, including anticoagulants, insulin, opioids, and concentrated electrolytes. (Bloom’s: Apply — QSEN S; NCLEX-NG: PhysI, SECE)
8. Construct evidence-based patient education for common medication regimens, including purpose, administration technique, side effects, and warning signs. (Bloom’s: Create — AACN D2; QSEN PCC)

---

Course Structure

Module	Title	Key Focus
1	Pharmacokinetics and Pharmacodynamics	ADME, receptor theory, therapeutic index
2	Drug Math: Dosage Calculations	Dimensional analysis, IV rates, weight-based dosing
3	Cardiovascular and Respiratory Pharmacology	Antihypertensives, anticoagulants, bronchodilators
4	Endocrine, Metabolic, and GI Pharmacology	Insulin, oral antidiabetics, thyroid, GI agents
5	Analgesics, Sedatives, and Neurological Agents	Opioids, NSAIDs, benzodiazepines, antiepileptics
6	Anti-Infective Pharmacology	Antibiotics, antifungals, antivirals
7	Safe Medication Administration Practices	Six rights, high-alert medications, error prevention
8	Case-Based Medication Management	Integrated clinical reasoning across drug classes

---

Module 1: Pharmacokinetics and Pharmacodynamics

Overview

Before a nurse can safely manage medications, they must understand the fundamental science of how drugs move through and act on the body. This module covers pharmacokinetics (ADME) and pharmacodynamics (receptor theory, dose-response), with emphasis on the clinical implications for nursing assessment, dose calculation, monitoring, and patient education.

For a detailed scientific reference, see the Pharmacology Fundamentals encyclopedia entry.

1.1 Pharmacokinetics: ADME

Pharmacokinetics is the study of what the body does to a drug across four sequential processes:

• Absorption — Drug movement from administration site to systemic circulation. Bioavailability (F) quantifies what fraction of the drug reaches the bloodstream intact. The first-pass effect substantially reduces the bioavailability of many orally administered drugs (e.g., morphine oral F ≈ 0.25).
• Distribution — Drug dispersal to tissues. Determined by plasma protein binding (only free drug is active), lipid solubility, and blood-brain barrier permeability. Hypoalbuminemia increases free drug fraction — relevant for highly protein-bound drugs such as phenytoin and warfarin.
• Metabolism — Enzymatic biotransformation, primarily in the liver via the CYP450 system. Drug interactions frequently occur through CYP enzyme induction (e.g., rifampin reduces drug levels) or inhibition (e.g., fluconazole increases drug levels).
• Excretion — Drug and metabolite elimination, predominantly renal. Creatinine clearance (CrCl) guides dose adjustment for renally cleared drugs. Half-life (t½) determines dosing interval and time to steady state (~5 half-lives).

1.2 Pharmacodynamics: Receptors and Response

Pharmacodynamics describes what a drug does to the body:

• Agonists activate receptors and produce a response; antagonists block receptors and inhibit the endogenous agonist or other drugs
• Efficacy = maximum achievable drug effect; potency = dose required to produce 50% of maximum effect
• Therapeutic index (TI) = TD₅₀ / ED₅₀; narrow-TI drugs (digoxin, warfarin, lithium, aminoglycosides, phenytoin) require routine drug level monitoring

1.3 Patient-Specific Pharmacokinetic Considerations

Patient Population	Key Pharmacokinetic Change	Nursing Implication
Neonates and infants	Immature hepatic enzymes; high body water fraction; low protein binding	Lower mg/kg doses for hepatically metabolized drugs; more frequent monitoring
Older adults	Reduced hepatic blood flow and enzyme activity; decreased GFR; lower albumin; increased body fat	Drugs accumulate more readily; start low, go slow; fall risk with CNS drugs
Patients with renal impairment	Decreased GFR → reduced renal clearance → drug accumulation	Adjust doses of renally excreted drugs; use CrCl/eGFR to guide decisions
Patients with hepatic impairment	Reduced first-pass effect; reduced protein synthesis; altered CYP activity	Increased bioavailability of oral drugs; avoid hepatotoxic agents
Obese patients	Increased Vd for lipophilic drugs; variable changes in clearance	Use actual or adjusted body weight depending on the drug and evidence base
Pregnant patients	Increased plasma volume, GFR, and CYP activity; protein binding changes	Many drugs require higher doses to achieve therapeutic levels; fetal exposure must be considered

Module 1 Practice Questions

1. A patient with cirrhosis is prescribed oral propranolol 40 mg twice daily. The nurse understands that the plasma concentration of propranolol will likely be higher than expected in this patient primarily because:

   • A) Renal clearance is increased in cirrhosis
   • B) The first-pass hepatic metabolism is reduced, increasing bioavailability ✓
   • C) Plasma protein binding is increased in liver disease
   • D) Distribution of propranolol into tissues is impaired by ascites

2. A nurse is caring for an 80-year-old patient with a creatinine of 1.8 mg/dL who is prescribed gentamicin. The nurse’s priority assessment is:

   • A) Monitor blood glucose every 4 hours
   • B) Auscultate lung sounds before each dose
   • C) Obtain drug levels and monitor for signs of nephrotoxicity and ototoxicity ✓
   • D) Ensure the patient’s INR is therapeutic before administration

---

Module 2: Drug Math — Dosage Calculations

Overview

Accurate drug dosage calculation is a non-negotiable clinical competency. This module provides systematic practice with dimensional analysis, IV infusion rate calculations, weight-based dosing, and pediatric calculations. Students should be able to perform all calculations independently, without relying solely on calculator apps, to maintain the mathematical reasoning skills needed to catch programming errors.

2.1 Dimensional Analysis Framework

The general dimensional analysis setup:

Desired unit = Given × (Conversion factor 1) × (Conversion factor 2) × ...

Every conversion factor is a fraction equal to 1 (numerator and denominator are equivalent amounts in different units). Units in the denominator of one factor cancel units in the numerator of the previous factor.

2.2 Oral and Parenteral Dose Calculations

Example A — Standard tablet calculation:

Order: Metoprolol succinate 37.5 mg PO daily. Available: 25 mg scored tablets.

tablets = 37.5 mg × (1 tablet / 25 mg) = 1.5 tablets

Administer 1.5 tablets (the tablet is scored, so splitting is appropriate).

Example B — Liquid dose calculation:

Order: Amoxicillin 500 mg PO. Available: 250 mg/5 mL oral suspension.

mL = 500 mg × (5 mL / 250 mg) = 10 mL

Example C — IV piggyback dose:

Order: Vancomycin 1,250 mg IV in 250 mL NS over 90 minutes. Available concentration: 5 mg/mL.

Volume = 1,250 mg ÷ 5 mg/mL = 250 mL ✓ (matches the prepared bag). Infusion rate = 250 mL / 1.5 hours = 167 mL/hour.

2.3 Continuous IV Infusion Rate Calculations

Example D — Simple continuous infusion:

Order: Potassium chloride 20 mEq IV in 100 mL NS over 4 hours.

mL/hour = 100 mL / 4 hours = 25 mL/hour

Example E — Drug concentration infusion:

Order: Heparin 1,400 units/hour IV. Available: 25,000 units heparin in 500 mL NS.

mL/hour = 1,400 units/hour × (500 mL / 25,000 units) = 28 mL/hour

2.4 Weight-Based Dosing

Example F — mcg/kg/min infusion (vasopressor):

Order: Dopamine 5 mcg/kg/min. Patient weight: 80 kg. Available: 400 mg dopamine in 250 mL D5W.

Step 1: Concentration = 400 mg × 1,000 mcg/mg = 400,000 mcg in 250 mL = 1,600 mcg/mL.

Step 2: Required dose = 5 mcg/kg/min × 80 kg = 400 mcg/min.

Step 3: Rate = 400 mcg/min × (60 min/hr) ÷ 1,600 mcg/mL = 15 mL/hour.

2.5 Pediatric Dosing

Pediatric doses are almost always calculated on a mg/kg or mg/kg/day basis. The nurse must:

1. Calculate the dose in mg from the ordered mg/kg and patient weight
2. Verify the calculated dose falls within the recommended range from a reliable reference
3. Calculate the volume to administer from the available concentration
4. For IV medications, obtain an independent double-check

Example G — Pediatric antibiotic:

Order: Ceftriaxone 50 mg/kg IV every 24 hours. Patient weight: 22 kg. Available: 500 mg in 50 mL NS (10 mg/mL).

Dose = 50 mg/kg × 22 kg = 1,100 mg. Volume = 1,100 mg ÷ 10 mg/mL = 110 mL to infuse.

2.6 IV Drip Rate Calculations (Gravity Infusion)

When infusing via gravity (without an electronic pump):

Drops/minute = (Volume in mL × Drop factor in gtt/mL) / Time in minutes

Example H: Infuse 500 mL NS over 4 hours via 20 gtt/mL tubing.

gtt/min = (500 mL × 20 gtt/mL) / (240 min) = 10,000 / 240 ≈ 42 gtt/min

Module 2 Practice Questions

1. A nurse is preparing to administer furosemide 60 mg IV push. The available concentration is 10 mg/mL. How many mL should the nurse draw up?

   • A) 4 mL
   • B) 5 mL
   • C) 6 mL ✓
   • D) 10 mL

2. A patient who weighs 70 kg is ordered norepinephrine 0.1 mcg/kg/min. The pharmacy delivers a standard concentration of 4 mg in 250 mL NS. What is the infusion rate in mL/hour?

   • A) 18 mL/hour
   • B) 26.25 mL/hour ✓
   • C) 32 mL/hour
   • D) 10.5 mL/hour

   Solution: Concentration = 4 mg × 1,000 mcg/mg = 4,000 mcg in 250 mL = 16 mcg/mL. Dose = 0.1 mcg/kg/min × 70 kg = 7 mcg/min × 60 min/hr = 420 mcg/hr. Rate = 420 mcg/hr ÷ 16 mcg/mL = 26.25 mL/hr.

---

Module 3: Cardiovascular and Respiratory Pharmacology

Overview

Cardiovascular and respiratory disorders are among the most common conditions managed in medical-surgical, critical care, and outpatient nursing settings. This module covers the major drug classes used to manage hypertension, heart failure, arrhythmias, coronary artery disease, and obstructive lung disease, with emphasis on mechanism of action, nursing assessment parameters, safety considerations, and patient education.

3.1 Antihypertensive Agents

Hypertension management typically involves one or more of the following drug classes, often in combination:

Class	Mechanism	Key Agents	Nursing Priorities
ACE Inhibitors	Block ACE → ↓ angiotensin II → vasodilation + ↓ aldosterone	Lisinopril, enalapril, ramipril	Monitor BP and K⁺; dry cough (switch to ARB); hold if K⁺ > 5.5 mEq/L or creatinine rising; contraindicated in pregnancy; angioedema (rare but life-threatening)
ARBs	Block AT₁ receptor → vasodilation	Losartan, valsartan, olmesartan	Same indications and monitoring as ACEi; no cough; contraindicated in pregnancy
Thiazide Diuretics	Block Na⁺-Cl⁻ cotransporter in distal tubule → natriuresis	Hydrochlorothiazide, chlorthalidone	Monitor K⁺, Na⁺, uric acid, glucose; less effective when GFR < 30 mL/min
Beta-Blockers	Block β₁ receptors → ↓ HR, contractility, renin	Metoprolol, atenolol, bisoprolol	Hold if HR < 60 bpm or SBP < 90 mmHg; never abruptly discontinue (rebound hypertension/angina); caution in asthma/COPD
Dihydropyridine CCBs	Block L-type Ca²⁺ channels → vasodilation (peripheral)	Amlodipine, nifedipine, felodipine	Monitor BP and edema; do not crush extended-release formulations
Non-Dihydropyridine CCBs	Block Ca²⁺ channels → vasodilation + ↓ HR/AV conduction	Diltiazem, verapamil	Monitor BP and HR; avoid with beta-blockers (severe bradycardia); constipation common with verapamil

3.2 Anticoagulant Therapy

Anticoagulants are among the most high-alert medications in clinical practice. Indications include venous thromboembolism (VTE) treatment and prophylaxis, atrial fibrillation stroke prevention, and mechanical heart valve protection.

Unfractionated Heparin (UFH):

• Mechanism: Potentiates antithrombin III → inhibits thrombin and Factor Xa
• Monitoring: aPTT (target 60–100 seconds or 1.5–2.5× control); anti-Xa level for obese patients or extremes of weight
• Antidote: Protamine sulfate (1 mg per 100 units of heparin)
• Nursing: Use a standardized heparin nomogram; independent double-check of pump rate; assess for bleeding every 4–8 hours

Low Molecular Weight Heparin (LMWH — Enoxaparin):

• Monitoring: Anti-Xa level for renal impairment, obesity, pregnancy; routine monitoring not required otherwise
• Antidote: Protamine sulfate (60–75% reversal)
• Nursing: Do not aspirate or rub subcut injection site; rotate sites; renal dose adjustment required when CrCl < 30 mL/min

Warfarin:

• Mechanism: Inhibits vitamin K-dependent clotting factors (II, VII, IX, X) and proteins C and S
• Monitoring: INR every 1–4 weeks when stable (target 2–3 for most indications; 2.5–3.5 for mechanical aortic valves)
• Antidote: Vitamin K (slow reversal); FFP or 4-factor PCC (rapid reversal)
• Interactions: Hundreds of drug and food interactions; check INR with any medication change; vitamin K–rich foods (leafy greens) decrease INR — consistency is more important than elimination

Direct Oral Anticoagulants (DOACs):

• Include: Rivaroxaban (Xarelto), apixaban (Eliquis), dabigatran (Pradaxa), edoxaban (Savaysa)
• Monitoring: No routine coagulation monitoring required; renal function at baseline and periodically
• Reversal: Andexanet alfa (Factor Xa inhibitors); idarucizumab (dabigatran)
• Nursing: Assess for bleeding at each encounter; do not crush or split capsules; renal dose adjustment required for most agents

3.3 Antiarrhythmic Agents

Antiarrhythmics are classified by the Vaughan Williams system:

Class	Mechanism	Examples	Nursing Considerations
Ia	Na⁺ channel block + K⁺ block → prolong AP duration	Quinidine, procainamide	Monitor QRS, QTc; lupus-like syndrome with procainamide
Ib	Na⁺ channel block → shorten AP duration	Lidocaine, mexiletine	CNS toxicity (tinnitus, seizures) at toxic levels; IV only for lidocaine
Ic	Strong Na⁺ channel block → markedly slow conduction	Flecainide, propafenone	Avoid post-MI; proarrhythmic risk
II	Beta-blockade	Metoprolol, esmolol, propranolol	Monitor HR and BP; do not abruptly discontinue
III	K⁺ channel block → prolong repolarization	Amiodarone, sotalol, dofetilide	QTc monitoring; amiodarone: pulmonary toxicity, thyroid effects, corneal deposits, photosensitivity; t½ 40–55 days
IV	Ca²⁺ channel block	Diltiazem, verapamil	Avoid with beta-blockers; monitor HR

3.4 Respiratory Pharmacology

Short-Acting Beta₂ Agonists (SABAs — albuterol):

• Rescue therapy for acute bronchospasm in asthma and COPD
• Onset: 5–15 minutes; duration: 4–6 hours
• Assess HR before and after (can cause tachycardia); teach correct MDI/spacer technique
• If a patient requires rescue inhaler more than 2 days per week, step up maintenance therapy

Inhaled Corticosteroids (ICS — budesonide, fluticasone):

• Maintenance therapy to reduce airway inflammation; not for acute relief
• Instruct patients to rinse mouth and gargle after each use to prevent oropharyngeal candidiasis
• Long-term high-dose use carries risk of systemic effects (adrenal suppression, reduced bone density)

Leukotriene Receptor Antagonists (LTRAs — montelukast):

• Oral maintenance therapy for mild persistent asthma and allergic rhinitis
• FDA black box warning: neuropsychiatric events (behavior change, suicidal thinking) — assess at each visit

---

Module 4: Endocrine, Metabolic, and Gastrointestinal Pharmacology

Overview

Diabetes is the most prevalent endocrine disorder in the United States, and insulin is one of the most high-alert medications in clinical practice. This module covers insulin types and protocols, oral antidiabetic agents, thyroid pharmacology, and common GI medications.

4.1 Insulin Therapy

Insulin Type	Onset	Peak	Duration	Clinical Use
Aspart, Lispro (rapid-acting)	10–30 min	1–3 hr	3–5 hr	Mealtime bolus; administer within 15 min of meal
Regular (short-acting)	30–60 min	2–4 hr	6–8 hr	Mealtime bolus (give 30 min before meal); IV insulin drips
NPH (intermediate-acting)	1–2 hr	6–12 hr	18–24 hr	Twice-daily basal coverage; roll to mix — never shake
Glargine, Detemir (long-acting)	1–2 hr	No pronounced peak	20–24 hr	Once-daily basal; never mix with other insulins; clear solution
Degludec (ultra-long)	1 hr	No peak	> 42 hr	Once-daily basal; greatest flexibility in dosing time

Hypoglycemia recognition and response:

• Mild-moderate (patient conscious): 15 g fast-acting carbohydrate (4 oz juice, 3–4 glucose tablets); recheck glucose in 15 minutes; repeat if still < 70 mg/dL (“15-15 rule”)
• Severe (unconscious or unable to swallow): 1 mg glucagon IM/subcut or intranasal; 50 mL D50W IV; continuous glucose monitoring

4.2 Oral Antidiabetic Agents

Class	Mechanism	Key Agents	Nursing Considerations
Biguanides	↓ Hepatic glucose production	Metformin	Hold 48 hr before/after iodinated contrast; hold when eGFR < 30 mL/min; GI side effects — take with food; does not cause hypoglycemia alone
Sulfonylureas	Stimulate pancreatic insulin secretion	Glipizide, glyburide	Hypoglycemia risk (especially glyburide in elderly); administer with first meal
DPP-4 Inhibitors	Inhibit DPP-4 → ↑ incretin → glucose-dependent insulin release	Sitagliptin	Well tolerated; minimal hypoglycemia; risk of pancreatitis
GLP-1 Agonists	Mimic GLP-1 → insulin release, ↓ glucagon, ↓ appetite	Semaglutide, liraglutide	GI side effects; pancreatitis risk; significant weight loss; injectable
SGLT-2 Inhibitors	Block renal glucose reabsorption → glucosuria	Empagliflozin, dapagliflozin	Risk of DKA (check ketones if symptoms), UTI/genital mycotic infections; hold before surgery
Thiazolidinediones	PPAR-γ agonists → improve insulin sensitivity	Pioglitazone	Fluid retention; avoid in HF; bladder cancer signal with pioglitazone

4.3 Thyroid Pharmacology

Levothyroxine (T4 replacement — hypothyroidism):

• Administer on an empty stomach 30–60 minutes before breakfast or as directed
• Consistency of timing is more important than specific time of day
• Many drugs impair absorption: calcium, iron, antacids — separate by at least 4 hours
• Monitor TSH 4–6 weeks after initiation or dose change; goal TSH 0.5–2.5 mU/L for most patients

Methimazole and Propylthiouracil (PTU — hyperthyroidism):

• Inhibit thyroid hormone synthesis
• Monitor CBC — agranulocytosis is a rare but serious adverse effect; instruct patients to report fever, sore throat, or mouth sores immediately
• PTU is preferred in first trimester of pregnancy; methimazole preferred otherwise

4.4 Gastrointestinal Agents

Drug/Class	Mechanism	Use	Nursing Considerations
Proton Pump Inhibitors (PPIs)	Irreversibly inhibit H⁺/K⁺-ATPase	GERD, peptic ulcer, stress ulcer prophylaxis	Take 30–60 min before first meal of day; long-term use: risk of hypomagnesemia, C. diff, fractures
H₂ Receptor Antagonists	Block H₂ receptors → ↓ acid	GERD, ulcer	Less acid suppression than PPIs; ranitidine removed from market (NDMA contamination)
Ondansetron (5-HT₃ antagonist)	Block serotonin at CTZ	Nausea/vomiting	Monitor QTc; serotonin syndrome risk when combined with serotonergic agents
Metoclopramide	D₂ antagonist + ↑ GI motility	Gastroparesis, GERD, nausea	Risk of tardive dyskinesia with long-term use (> 3 months) — FDA black box warning
Lactulose	Osmotic laxative	Hepatic encephalopathy, constipation	Goal: 2–3 soft stools/day for encephalopathy; monitor for electrolyte imbalance with overuse

---

Module 5: Analgesics, Sedatives, and Neurological Agents

Overview

Pain is one of the most common reasons patients seek healthcare, and its management requires careful balance between adequate relief and prevention of adverse effects — particularly respiratory depression with opioids. This module covers the analgesic ladder, opioid pharmacology, non-opioid analgesics, sedation monitoring, and common neurological agents.

5.1 The WHO Analgesic Ladder and Multimodal Analgesia

The World Health Organization’s three-step analgesic ladder guides pharmacological pain management:

1. Step 1 (mild pain): Non-opioid analgesics — acetaminophen, NSAIDs
2. Step 2 (moderate pain): Low-dose opioids or tramadol ± non-opioid adjuvants
3. Step 3 (severe pain): Strong opioids (morphine, hydromorphone, oxycodone, fentanyl) ± non-opioid adjuvants

Multimodal analgesia — combining drugs from different classes at lower individual doses to achieve adequate pain control while minimizing single-agent adverse effects — is the evidence-based standard of care for surgical and chronic pain management.

5.2 Opioid Pharmacology

Mechanism: Opioids bind μ-, κ-, and δ-opioid receptors in the CNS and peripheral nervous system, producing analgesia, sedation, euphoria, respiratory depression, decreased GI motility, and miosis.

Opioid	Onset (IV/PO)	Duration	Key Notes
Morphine	5 min IV / 30–60 min PO	3–5 hr	Gold standard; active metabolite accumulates in renal failure
Hydromorphone	5 min IV	3–4 hr	5–7× more potent than morphine; common PCA agent
Fentanyl	1–2 min IV	30–60 min (IV bolus)	100× more potent than morphine; transdermal patch: 12–24 hr onset, 72-hr duration
Oxycodone	30–60 min PO	4–6 hr	Oral only as single agent; combination products limit maximum dose
Tramadol	1 hr PO	4–6 hr	Weak opioid + SNRI; lowers seizure threshold; serotonin syndrome risk

Opioid-induced constipation: Occurs in virtually all patients on scheduled opioids. Begin a stimulant laxative (senna ± docusate) prophylactically at the start of opioid therapy; do not wait for constipation to develop.

Naloxone (Narcan): Opioid antagonist for respiratory depression. Dose: 0.4–2 mg IV/IM/IN; titrate to adequate respiratory rate (> 10/min) while maintaining analgesia. Short half-life (30–90 min) — renarcotization risk with long-acting opioids; may require repeat dosing or naloxone infusion.

5.3 Non-Opioid Analgesics

Acetaminophen:

• Mechanism: Inhibits central prostaglandin synthesis; mechanism not fully elucidated
• Maximum dose: 4 g/day in healthy adults; 2 g/day for chronic alcohol use, liver disease, or malnutrition
• Critical nursing action: Check all combination products for hidden acetaminophen (e.g., Vicodin = oxycodone + acetaminophen; Percocet = oxycodone + acetaminophen; Nyquil, Tylenol PM)
• Antidote for overdose: N-acetylcysteine (Mucomyst)

NSAIDs:

• Mechanism: Inhibit COX-1 and COX-2 → reduced prostaglandin synthesis → analgesia, anti-inflammatory, antipyretic effects
• Contraindications: Active peptic ulcer disease, renal impairment (GFR < 30 mL/min), third-trimester pregnancy, post-CABG surgery
• Adverse effects: GI bleeding (COX-1 inhibition reduces gastric cytoprotection); renal impairment; platelet dysfunction; cardiovascular risk with long-term use
• Administer with food or milk to reduce GI irritation; offer PPI for patients at GI risk

5.4 Sedation and Anxiolytic Agents

Benzodiazepines (lorazepam, midazolam, diazepam):

• Mechanism: Potentiate GABA-A receptor → CNS depression → anxiolysis, sedation, amnesia, muscle relaxation, anticonvulsant effects
• Antidote: Flumazenil (short-acting; re-sedation risk — monitor closely)
• Nursing: Assess respiratory rate and sedation level (RASS) before each dose; fall precautions; avoid in older adults (Beers Criteria)

Propofol:

• Short-acting IV sedative used in ICU and procedure settings
• Monitor for propofol infusion syndrome (PRIS) with high-dose prolonged infusions: metabolic acidosis, rhabdomyolysis, cardiac failure
• Lipid-based formulation: strict aseptic technique; discard opened vials within 12 hours

5.5 Neurological Agents

Antiepileptic Drugs (AEDs):

Drug	Mechanism	Monitoring	Key Considerations
Phenytoin/Fosphenytoin	Na⁺ channel stabilization	Phenytoin level (target 10–20 mcg/mL); CBC; LFTs	Narrow TI; zero-order kinetics at high doses; numerous interactions; IV infusion rate ≤ 50 mg/min (hypotension, arrhythmia); gingival hyperplasia with long-term use
Valproate	Multiple mechanisms	Valproate level; LFTs; ammonia; platelets	Highly teratogenic (neural tube defects); hepatotoxicity; thrombocytopenia; pancreatitis
Levetiracetam	Unknown; SV2A modulation	Renal function for dose adjustment	Well tolerated; behavioral/mood changes; no significant drug interactions
Carbamazepine	Na⁺ channel stabilization	Drug level; CBC; LFTs; Na⁺	Induces own metabolism and many other drugs; hyponatremia; teratogenic; Stevens-Johnson syndrome risk (HLA-B*1502 in Asian populations)

---

Module 6: Anti-Infective Pharmacology

Overview

Antimicrobial stewardship — the practice of using antibiotics appropriately, only when indicated, at the correct dose and duration — is a QSEN safety competency and a public health imperative. This module covers the major antibiotic classes, antifungals, and antivirals, with emphasis on mechanism of action, spectrum of coverage, resistance patterns, and nursing monitoring.

6.1 Antibiotic Classes

Class	Mechanism	Spectrum	Key Agents	Nursing Considerations
Penicillins	Inhibit cell wall synthesis (PBP binding)	Gram-positive (broad penicillins extend to gram-negative)	Amoxicillin, ampicillin, nafcillin, piperacillin-tazobactam	Assess PCN allergy; cross-reactivity with cephalosporins (~1–2%); schedule doses at even intervals
Cephalosporins	Inhibit cell wall synthesis	Gram-positive (1st gen) → broader gram-negative with each generation	Cefazolin (1st), ceftriaxone (3rd), cefepime (4th)	Assess PCN/cephalosporin allergy; ceftriaxone: avoid calcium-containing IV fluids in neonates
Carbapenems	Inhibit cell wall synthesis; broadest spectrum	Gram-positive, gram-negative, anaerobes (except MRSA)	Meropenem, imipenem	Reserve for resistant organisms; monitor for seizures (imipenem); C. diff risk
Fluoroquinolones	Inhibit DNA gyrase and topoisomerase IV	Gram-negative, atypicals, some gram-positive	Ciprofloxacin, levofloxacin	Black box: tendon rupture, peripheral neuropathy, CNS effects; avoid in children/pregnancy; QTc prolongation; photosensitivity
Macrolides	Inhibit 50S ribosome → protein synthesis block	Gram-positive, atypicals	Azithromycin, erythromycin, clarithromycin	QTc prolongation; drug interactions via CYP3A4 inhibition; GI motility effects
Tetracyclines	Inhibit 30S ribosome → protein synthesis block	Broad spectrum, atypicals, MRSA (some)	Doxycycline, minocycline	Avoid in children < 8 and pregnancy (teeth/bone); take upright; photosensitivity; dairy decreases absorption
Vancomycin	Inhibits cell wall synthesis (D-Ala–D-Ala binding)	Gram-positive, MRSA	Vancomycin	Monitor AUC/MIC (or trough 15–20 mcg/mL); Red Man Syndrome with rapid infusion (infuse over ≥60 min); nephrotoxic + ototoxic
Aminoglycosides	Inhibit 30S ribosome irreversibly	Gram-negative (synergy with PCN for gram-positive)	Gentamicin, tobramycin, amikacin	Narrow TI; nephrotoxic and ototoxic; monitor drug levels; use extended-interval dosing when possible
Metronidazole	DNA strand breakage (anaerobes/protozoa)	Anaerobes, C. diff, protozoa	Metronidazole (Flagyl)	Disulfiram-like reaction with alcohol; avoid alcohol during and 48 hr after; metallic taste
Linezolid	Inhibit 50S subunit (unique binding site)	Gram-positive, MRSA, VRE	Linezolid	Serotonin syndrome with SSRIs; monoamine oxidase inhibitor (MAOI) properties; thrombocytopenia with > 2-week use; monitor CBC weekly

6.2 Antimicrobial Stewardship: Nursing Role

Nurses are essential partners in antimicrobial stewardship programs (ASPs). Key nursing responsibilities include:

• Obtain cultures before the first antibiotic dose whenever possible (blood, urine, wound, sputum as ordered) — cultures drawn after antibiotics are started are less reliable
• Communicate culture and sensitivity results to the provider promptly to facilitate de-escalation to the narrowest appropriate agent
• Monitor for superinfections: Clostridioides difficile (new or worsening diarrhea after antibiotics) and oral/vaginal Candida (thrush, vaginal discharge, pruritus)
• Document allergy history accurately: distinguish true allergies from intolerances (nausea, loose stools) — allergy misclassification leads to unnecessary use of broader-spectrum or more toxic agents
• Educate patients to complete the full prescribed course and not to share antibiotics

6.3 Antifungal Agents

Agent	Use	Nursing Considerations
Fluconazole	Systemic Candida, cryptococcal meningitis	Strong CYP3A4/2C9 inhibitor — elevates warfarin, statins; hepatotoxicity with prolonged use
Micafungin, Caspofungin	Invasive Candida, Aspergillus	Echinocandins; IV only; well tolerated; fewer drug interactions
Amphotericin B	Severe systemic fungal infections	Pre-medicate with acetaminophen, diphenhydramine, hydration to reduce infusion reactions; nephrotoxic — monitor BMP daily; administer in D5W only (not NS)
Voriconazole	Invasive Aspergillus, resistant Candida	Visual disturbances (photopsia) — counsel patients; photosensitivity; hepatotoxic; multiple drug interactions

---

Module 7: Safe Medication Administration Practices

Overview

This module synthesizes the safety principles embedded throughout the course into actionable practice guidelines. Students will apply the six rights systematically, identify and manage high-alert medications, develop strategies for error prevention, and practice reporting within a just culture framework.

7.1 The Six Rights — Systematic Application

The six rights are not a checklist to complete quickly; they are a deliberate cognitive process that requires distraction-free attention at the bedside.

Right	Verification Method	Common Failure Mode
Right Patient	Scan barcode + verbally confirm name and DOB; check armband	Relying on room number or facial recognition
Right Medication	Compare label to MAR three times: when taking from drawer, when preparing, when at bedside	”Sounds like” errors (e.g., hydroxyzine vs. hydralazine)
Right Dose	Independently calculate; verify dose makes clinical sense	Accepting automated pump calculation without verification
Right Route	Confirm route is ordered and appropriate for this patient	Administering an IV medication via oral route (or vice versa)
Right Time	Administer within window; verify no missed or duplicate doses	Early administration of time-sensitive medications
Right Documentation	Document after administration; include patient response to PRN medications	Documenting before administration (“pre-charting”)

7.2 High-Alert Medication Safe Practice Checklist

High-alert medications require enhanced verification beyond the six rights. The following checklist applies to the most common high-alert categories:

Insulin Safe Practice Checklist:

• Blood glucose obtained within appropriate time frame before administration
• Correct insulin type verified against the MAR (e.g., glargine vs. aspart)
• Correct dose verified — independent double-check completed
• Correct patient confirmed with two identifiers and BCMA scan
• Correct route confirmed (subcutaneous vs. IV — different concentrations)
• Meal tray available (for rapid-acting insulin) or confirmed delay documented
• Patient teaching completed or reinforced

Anticoagulant Safe Practice Checklist:

• Indication verified
• Relevant lab values reviewed (INR, aPTT, anti-Xa, CBC, renal function)
• For IV heparin: independent double-check of pump rate and concentration; standardized nomogram in use
• Signs and symptoms of bleeding assessed (neurological status for intracranial bleed; GI, genitourinary, skin)
• Antidote availability confirmed (protamine for heparin/LMWH; vitamin K/PCC for warfarin; reversal agents for DOACs)
• Patient instructed to report unusual bleeding or bruising

Opioid Safe Practice Checklist:

• Pain score obtained using validated scale
• Respiratory rate ≥ 12/min; SpO₂ ≥ 92% (or per ordered parameters)
• Sedation level assessed (RASS score)
• Naloxone immediately accessible
• PCA programming independently verified (if applicable): drug, concentration, demand dose, lockout interval, 4-hour limit
• Constipation prophylaxis prescribed and administered

Concentrated Electrolyte Safe Practice Checklist:

• Concentrated KCl IV is a never event as an IV push — always diluted per policy
• Concentration and rate verified against facility policy
• Independent double-check of pump settings
• Patient on continuous cardiac monitoring during infusion if KCl concentration > 10 mEq/100 mL

7.3 Medication Error Prevention Strategies

Evidence-based strategies to reduce medication errors in nursing practice:

• Bar-code medication administration (BCMA): Scan patient armband and medication barcode at the bedside; do not bypass the scanner
• Eliminate distractions: Many institutions use “no interruption zones” during medication preparation; use a visual cue (e.g., medication safety vest) to signal preparation time
• Independent double-checks: Required for high-alert medications; must be truly independent — the checking nurse should not be told the expected answer before calculating
• ISMP “Do Not Use” abbreviations: Avoid dangerous abbreviations: U (units), IU, QD/QOD, trailing zeros (1.0 mg → 1 mg), naked decimal points (.5 mg → 0.5 mg)
• Tall man lettering: Recognizing look-alike/sound-alike drugs: hydrALAZINE vs. hydrOXYzine; DOPamine vs. DOBUTamine; EPINEPHrine vs. EPHEDrine
• Reconciliation at every transition of care: Admission, transfer, discharge — compare home medications to current orders and resolve all discrepancies

7.4 Medication Error Reporting and Just Culture

When a medication error occurs or is discovered:

1. Ensure patient safety first — assess the patient and notify the provider
2. Document the error objectively in the medical record
3. Report through the facility’s incident reporting system (e.g., RL Solutions, MedMarx)
4. Participate in root cause analysis if requested
5. Do not alter or omit documentation related to the error

A just culture distinguishes between human error (systems-based response), at-risk behavior (coaching and systems redesign), and reckless behavior (accountability). Nurses should report errors without fear of punitive retaliation, understanding that transparent reporting is the foundation of continuous safety improvement.

---

Module 8: Case-Based Medication Management

Overview

This module integrates pharmacological knowledge, drug math, safety practices, and clinical judgment through three representative case studies. Each case presents a patient scenario, medication management challenges, and NCLEX-NG style questions requiring higher-order reasoning.

---

Case Study 1: The Patient with Heart Failure and Type 2 Diabetes

Patient: Mr. R.T., 67-year-old male. Admitted with acute decompensated heart failure (ADHF). PMH: HFrEF (EF 30%), type 2 diabetes mellitus, hypertension, CKD stage 3a (eGFR 48 mL/min).

Current medications on admission:

• Furosemide 40 mg PO daily
• Carvedilol 12.5 mg PO BID
• Lisinopril 5 mg PO daily
• Metformin 1,000 mg PO BID
• Glipizide 5 mg PO before breakfast
• Insulin glargine 20 units subcut at bedtime
• Atorvastatin 40 mg PO at bedtime

Admission orders include:

• Furosemide 80 mg IV push now, then 40 mg IV every 12 hours
• Hold lisinopril × 48 hours (BP 88/52 mmHg on admission)
• Hold metformin (IV contrast CT planned)
• Continuous cardiac monitoring
• Daily BMP and BNP

Clinical questions:

1. Why was lisinopril held on this patient? The patient’s admission blood pressure is 88/52 mmHg. Lisinopril, an ACE inhibitor, reduces systemic vascular resistance and preload. Administration in a patient with SBP < 90 mmHg risks further hypotension and organ hypoperfusion, particularly in the context of reduced cardiac output from ADHF.

2. Why was metformin held? Mr. R.T. is scheduled for a CT scan with iodinated contrast. Iodinated contrast can cause acute kidney injury, which impairs renal clearance of metformin. Metformin accumulation causes lactic acidosis — a potentially fatal complication. Per ADA and radiology guidelines, metformin should be held 48 hours before and after contrast administration in patients with eGFR < 60 mL/min.

3. The nurse is preparing IV furosemide 80 mg. Available: furosemide 10 mg/mL. How many mL should the nurse draw up? 80 mg ÷ 10 mg/mL = 8 mL. IV furosemide should be administered no faster than 4 mg/min — administer 80 mg over at least 2 minutes.

4. Mr. R.T. becomes hypoglycemic (blood glucose 52 mg/dL) at 1400. He is alert and able to swallow. What is the nurse’s priority action? Administer 15 g of fast-acting carbohydrate orally (four glucose tablets, 4 oz of juice, or 4 oz of regular soda). Recheck blood glucose in 15 minutes. If still < 70 mg/dL, repeat treatment. Notify the provider and document. Consider whether glipizide dose requires adjustment given reduced oral intake.

---

Case Study 2: The Post-Operative Patient with Pain Management Challenges

Patient: Ms. J.K., 54-year-old female. Postoperative day 1 following right hemicolectomy for colon cancer. PMH: Anxiety disorder (sertraline 100 mg PO daily), asthma (albuterol PRN, budesonide/formoterol 160/4.5 mcg inhaled BID), moderate hepatic steatosis.

Current pain orders:

• Ketorolac 15 mg IV every 6 hours × 48 hours (post-op days 0–1)
• Hydromorphone 0.2 mg IV every 3 hours PRN (pain ≥ 5/10)
• Acetaminophen 650 mg IV every 6 hours scheduled
• Ondansetron 4 mg IV every 6 hours PRN (nausea)

At 0800 assessment: Pain 7/10, respiratory rate 14/min, SpO₂ 96% on 2L/NC, RASS −1 (slightly drowsy), bowel sounds hypoactive.

Clinical questions:

1. Is it safe to administer hydromorphone 0.2 mg IV at this time? What assessment findings support your decision? Yes, it is safe to administer. The patient’s respiratory rate is 14/min (≥ 12/min), SpO₂ is 96%, and RASS is −1 (acceptable — mild drowsiness is expected post-operatively). Pain is 7/10 (above threshold for PRN dose). The nurse should reassess respiratory rate, SpO₂, and sedation at 15–30 minutes post-administration and ensure naloxone is accessible.

2. The nurse notes that Ms. J.K. is receiving sertraline and ondansetron concurrently. What drug interaction concern should be communicated to the provider? Both sertraline (SSRI) and ondansetron (5-HT₃ antagonist) have serotonergic activity and can contribute to QTc prolongation. The combination poses a risk of serotonin syndrome (though primarily a concern with serotonergic drugs that increase synaptic serotonin) and additive QTc prolongation. The nurse should notify the provider of this combination and request an ECG to assess baseline QTc. An alternative antiemetic (e.g., metoclopramide) may be preferred, though it carries its own risks.

3. The provider orders the maximum acetaminophen dose. The nurse knows Ms. J.K. has moderate hepatic steatosis. What is the nurse’s priority response? The nurse should clarify the order with the provider. In patients with liver disease, the maximum safe dose of acetaminophen is typically reduced to 2 g/day (from the standard 4 g/day) to reduce the risk of hepatotoxicity. The nurse should request that the scheduled dose be adjusted accordingly.

---

Case Study 3: The Patient Receiving Anticoagulation

Patient: Mr. D.W., 72-year-old male. Admitted with atrial fibrillation with rapid ventricular response. PMH: Hypertension, stage 2 CKD (eGFR 52 mL/min), remote history of peptic ulcer disease. CHA₂DS₂-VASc score = 4 (stroke risk: high).

Orders:

• Rate control: Diltiazem 0.25 mg/kg IV bolus over 2 minutes, then 5–15 mg/hour continuous infusion
• Anticoagulation: Apixaban 5 mg PO BID (started once HR controlled)
• VTE prophylaxis: Not required (therapeutic anticoagulation in place)

Diltiazem bolus calculation: Patient weight 88 kg. Dose = 0.25 mg/kg × 88 kg = 22 mg IV. Available: diltiazem 5 mg/mL. Volume = 22 mg ÷ 5 mg/mL = 4.4 mL administered over 2 minutes.

Clinical questions:

1. Why was apixaban selected over warfarin for this patient? DOACs such as apixaban have superior efficacy and safety profiles compared to warfarin in non-valvular atrial fibrillation (ARISTOTLE trial). Apixaban requires no routine INR monitoring, has fewer food and drug interactions, and has a lower rate of intracranial hemorrhage than warfarin. Given Mr. D.W.’s CKD stage 2 (eGFR 52 mL/min), apixaban is appropriate; the standard dose is 5 mg BID (dose reduction to 2.5 mg BID required if ≥ 2 of the following: age ≥ 80, weight ≤ 60 kg, creatinine ≥ 1.5 mg/dL).

2. What patient teaching should the nurse provide regarding apixaban?

   • Take exactly as prescribed; do not skip or double doses
   • Report unusual or prolonged bleeding: blood in urine, stools, or vomit; excessive bruising; prolonged bleeding from cuts; severe headache or sudden vision changes (signs of intracranial hemorrhage)
   • Do not take aspirin, ibuprofen, naproxen, or other NSAIDs unless specifically directed by the provider — increases bleeding risk
   • Inform all healthcare providers (including dentist) that you take apixaban before any procedures
   • Do not stop apixaban without talking to your provider first — stopping increases stroke risk
   • If a dose is missed, take it as soon as remembered the same day; do not double up the next day
   • Store at room temperature; original container

3. The nurse notes that diltiazem is ordered and Mr. D.W.’s HR is currently 62 bpm. What is the nurse’s priority action before starting the diltiazem infusion? The nurse should hold the diltiazem infusion and notify the provider. The heart rate of 62 bpm is already below the typical target range for rate control in atrial fibrillation (generally 60–80 bpm at rest), and initiating a diltiazem infusion (a calcium channel blocker that slows AV conduction) risks further bradycardia. The nurse should document the current HR, report to the provider using SBAR, and await revised orders before proceeding.

---

Course Summary and Synthesis

Pharmacology for Nurses is, at its core, a course about patient safety through knowledge. Every concept covered — from the subtleties of CYP enzyme interactions, to the precision of dimensional analysis, to the deliberate systematization of the six rights — exists in service of one outcome: patients receive the right medication, at the right dose, safely administered, with full understanding of its purpose and effects.

The major themes of this course are:

• Science informs safety: Understanding pharmacokinetics and pharmacodynamics allows nurses to anticipate adverse effects, recognize toxicity, and advocate for dose adjustments in vulnerable populations — rather than simply following orders mechanically.
• Accuracy in drug math is non-negotiable: A single decimal point error can be lethal. Dimensional analysis provides a systematic, verifiable framework that reduces error and builds confidence.
• High-alert medications demand heightened vigilance: Insulin, anticoagulants, opioids, and concentrated electrolytes appear routinely in nursing practice and carry disproportionate harm potential. The checklists in this course are not bureaucratic exercises — they are proven error-reduction strategies.
• Clinical judgment integrates pharmacology: The case studies in Module 8 illustrate that pharmacological decisions are never made in isolation. Patient history, organ function, concurrent medications, and patient values all shape the safe and effective use of medications.
• Antimicrobial stewardship is a nursing competency: Nurses who understand antibiotic mechanisms, resistance patterns, and the principle of de-escalation are essential partners in the global effort to preserve the effectiveness of antimicrobial agents.

For continued learning, students are encouraged to:

• Use the Pharmacology Fundamentals encyclopedia entry as a scientific reference throughout clinical rotations
• Explore individual drug monographs in the pharmacology reference collection for clinical detail on specific agents
• Complete the Pharmacology for Nurses practice quiz to assess and reinforce learning
• Consult current clinical resources (Micromedex, Lexicomp, or institutional drug databases) for patient-specific clinical decisions

---

References and Resources

• American Association of Colleges of Nursing (AACN). (2021). The essentials: Core competencies for professional nursing education. https://www.aacnnursing.org
• American Geriatrics Society Beers Criteria Update Expert Panel. (2023). American Geriatrics Society 2023 updated AGS Beers Criteria® for potentially inappropriate medication use in older adults. Journal of the American Geriatrics Society, 71(7), 2052–2081.
• Brunton, L. L., Hilal-Dandan, R., & Knollmann, B. C. (Eds.). (2018). Goodman & Gilman’s: The pharmacological basis of therapeutics (13th ed.). McGraw-Hill.
• Institute for Safe Medication Practices (ISMP). (2023). ISMP list of high-alert medications in acute care settings. https://www.ismp.org
• Lehne, R. A., & Rosenthal, L. D. (2022). Pharmacology for nursing care (11th ed.). Elsevier.
• NCSBN. (2023). Next generation NCLEX (NGN) test plan. https://www.ncsbn.org
• World Health Organization. (2022). Medication safety in transitions of care. https://www.who.int